AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Inclusion Criteria

• •For Subjects with Refractory Rheumatoid Arthritis (RA):
• •Documented diagnosis of RA, meeting the 2010 ACR/EULAR classification criteria.
• •Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA) positive.
• •High-sensitivity C-reactive protein (hs-CRP) \> 3 mg/L or Erythrocyte Sedimentation Rate (ESR) \> 28 mm/hr.
• •Have had prior treatment for a period of at least 12 weeks with a biologic disease modifying anti-rheumatic drug and were deemed refractory by the treating physician.
• •Minimum of six swollen joint counts (SJC) and six tender joint counts (TJC) according to joint assessment.
• •For subjects with Sjögren's Disease (SjD)
• •Prior diagnosis of Primary SjD as per 2016 ACR/EULAR criteria with confirmatory diagnosis in the 24 weeks preceding screening.
• •Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) \> 6.
• •Salivary Flow Rate \> 0.1 mL/min on stimulation.
• +9 more criteria